ANTX
AN2 Therapeutics, Inc.·Healthcare
2.97
2.623%(−0.08)
Market ClosedLast Updated: — ET
52W L: $1.0052W H: $6.91
ANTX NEWS
businesswire.com
Mar 31
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase (LeuRS), for the treatment of pulmonary disease caused by Mycobacterium abscessu.
businesswire.com
Mar 17
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2025. “Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2's boron chemistry pipeline and.
benzinga.com
Mar 11
AN2 Therapeutics Stock Cools Off After 90% Rally
AN2 Therapeutics Inc. (NASDAQ: ANTX) shares were down during Wednesday's premarket session in a volatile session. At the open, the stock recovered the losses.
benzinga.com
Mar 9
AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the clinical-stage biopharmaceutical company announced a $40 million private placement financing. Here's what investors need to know.
businesswire.com
Mar 9
AN2 Therapeutics Announces $40 Million Private Placement Financing
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $40 million, before deducting placement agent fees and other expenses. The private placement includes participation from Coastlands C.
businesswire.com
Mar 3
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer characterized by overproduction of red blood cells in the bone marrow. This overproduction.
